Tesamorelin vs Sermorelin: What the Evidence Shows

How tesamorelin vs sermorelin differs at the start

Tesamorelin and sermorelin are two protein-chain drugs. Both copy a brain message that prompts growth hormone. Sermorelin is the shorter drug. It contains 29 building blocks. Tesamorelin contains all 44 building blocks from the natural message ^[1]. One added part also slows tesamorelin's breakdown.

The research differs too. Tesamorelin has large studies and FDA approval for one HIV use ^[1][5]. Sermorelin has far less recent study work.

No direct comparison can tell which drug fits your care.

How each drug affects the growth gland

Both drugs carry a similar hormone message. Both reach cells in the small growth gland. Those cells then release growth hormone. That first step is alike. The chain lengths and breakdown times differ.

Tesamorelin uses the longer chain described above. Its added piece has one task: protect one end ^[1]. Without that part, the body breaks the natural message down within minutes. Sermorelin uses a shorter chain and lacks the same guard. It breaks down faster.

Tesamorelin made IGF-1 stay raised after the drug level fell ^[11]. No direct study here tested how long sermorelin raised that hormone.

What tesamorelin and sermorelin share and do not

1. Growth gland: Both drugs bring its cells a similar message ^[4]. Hormone change: Both prompt your own growth hormone and the liver-made hormone described above. Neither drug supplies ready-made growth hormone ^[11].
2. Protein chain: Tesamorelin has the longer chain ^[1]. Sermorelin has the shorter one ^[1]. Breakdown: An added part slows tesamorelin's breakdown. Sermorelin lacks that same part ^[1][4]. Study amount: Tesamorelin was studied at 2 mg once daily under the skin ^[1][2]. Approval: In 2010, the FDA approved tesamorelin for HIV-related fat buildup ^[5]. Organized sports ban both drugs.

Tesamorelin kept the liver-made hormone raised after its own blood level fell ^[11]. That finding doesn't compare the two drugs face to face.

What the tesamorelin and sermorelin studies show

Tesamorelin has the larger study record. Two main Phase 3 studies covered HIV-related fat buildup. These were large, late tests before approval. The first included 412 people ^[1]. A 52-week follow-up came next ^[2][6]. Another study checked liver fat ^[3]. A small study followed healthy men ^[4]. Other work asked who was more likely to respond ^[10]. One study tracked drug and hormone levels ^[11]. In 2026, one review joined five trials ^[13]. The record led to FDA approval for the HIV use in 2010 ^[5].

Sermorelin has far less recent proof. Its newer study record is much thinner. Even tesamorelin's large studies covered one group with HIV.

The proof differs sharply, but it can't choose a drug for you.

What tesamorelin vs sermorelin cannot tell you

No study here tested tesamorelin against sermorelin. The evidence can't show that one works better. That applies to fat loss, hormone rise, and safety. A page comparison isn't a direct test.

Tesamorelin's limits still matter. Its clear benefits came from adults with HIV-related fat buildup ^[1][2]. The deep fat came back when treatment ended ^[2][6]. FDA approval covers only that use ^[5]. Sport rules also ban the drug.

Tesamorelin vs sermorelin compares their design and research. The side effects and health reasons to avoid tesamorelin need a separate look.